Skip to main content

Table 1 Characteristics of the patients with AxSpA included in the study

From: Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study

  Total Based on the left sacroiliac joint damage p value Based on the right sacroiliac joint damage p value
0 grade 1 grade 2 grade 3 grade 4 grade 0 grade 1 grade 2 grade 3 grade 4 grade
Number of cases (n) 186 4 8 73 72 29 NA 4 10 74 72 26 NA
Age (years) 26.4 ± 8.7 25.3 ± 5.4 29.4 ± 10.7 24.9 ± 8.7 27. 6 ± 8.3 26.5 ± 9.2 0.138 25.3 ± 5.4 25.7 ± 9.4 25.0 ± 8.6 27.9 ± 8.5 26.7 ± 9.4 0.133
Male/female (n) 143/43 3/1 6/2 55/18 54/18 25/4 0.763 3/1 7/3 57/17 53/19 23/3 0.564
AxSpA duration (years) 4.3 ± 4.0 0.8 ± 0.3 4.4 ± 2.5 3.1 ± 3.1 4.8 ± 3.7 6.9 ± 5.6 <0.001 0.8 ± 0.3 4.5 ± 2.9 2.8 ± 2.2 5.1 ± 4.3 7.0 ± 5.5 <0.001
HLA-B27 (+/-) (n) 164/22 3/1 6/2 68/8 65/7 25/4 0.725 3/1 9/1 64/10 66/6 22/4 0.741
ESR (mm/h) 25.1 ± 22.1 9.5 ± 10.6 10.1 ± 8.9 20.2 ± 16.5 29.1 ± 24.8 33.7 ± 25.7 0.002 9.5 ± 10.6 23.8 ± 20.1 19.2 ± 17.2 28.3 ± 23.9 35.8 ± 26.3 0.007
CRP (mg/l) 14.3 ± 17.5 1.0 ± 0.5 3.1 ± 2.4 9.2 ± 13.1 16. 6 ± 17.2 26.0 ± 23.4 <0.001 1.0 ± 0.5 9.4 ± 15.6 9.9 ± 14.3 15.1 ± 15.9 28.1 ± 23.8 <0.001
Total back pain# 4.9 ± 2.8 1.3 ± 0.5 1.9 ± 1.4 4.5 ± 2.6 5.4 ± 2.6 6.3 ± 2.8 <0.001 1.3 ± 0.5 3.6 ± 3.2 4.5 ± 2.6 5.2 ± 2.6 6.6 ± 2.8 <0.001
PGA of disease activity# 5.6 ± 3.0 2.5 ± 1.9 2.5 ± 1.8 5.3 ± 2.8 5.9 ± 2.9 7.0 ± 2.9 <0.001 2.5 ± 1.9 4.4 ± 3.7 5.1 ± 2.8 5.9 ± 2.7 7.3 ± 3.0 0.002
Pain and swelling of peripheral arthritis# 0.2 ± 0.5 NA 0.3 ± 0.4 0.2 ± 0.4 0.3 ± 0.5 0.4 ± 0.6 0.249 NA 0.2 ± 0.4 0.2 ± 0.4 0.3 ± 0.5 0.4 ± 0.6 0.227
Duration of morning stiffness# 5.4 ± 2.8 2.8 ± 1.0 2.0 ± 1.3 5.1 ± 2.7 5.8 ± 2.6 6.4 ± 2.9 <0.001 2.8 ± 1.0 4.0 ± 3.6 4.9 ± 2.6 5.8 ± 2.5 6.7 ± 2.9 0.003
ASDAS (scores) 2.7 ± 1.1 1.0 ± 0.2 1.4 ± 0.4 2.4 ± 1.3 3.0 ± 1.3 3.5 ± 1.5 <0.001 1.0 ± 0.2 2.1 ± 1.6 2.4 ± 1.3 2.9 ± 1.3 3.6 ± 1.6 <0.001
BASFI (scores) 4.3 ± 1.1 1.9 ± 0.8 2.5 ± 0.9 4.0 ± 1.0 4.6 ± 0.7 4.9 ± 0.8 <0.001 1.9 ± 0.8 3.1 ± 1.5 4.1 ± 1.0 4.5 ± 0.8 4.9 ± 0.8 <0.001
Use of NSAIDs (ever/never) (n) 169/17 0/4 8/0 68/5 67/5 26/3 <0.001 0/4 10/0 70/4 66/6 23/3 <0.001
Use of DMARDs (≥3/<3 months) (n) 169/17 1/3 6/2 69/4 68/4 25/4 0.005 1/3 8/2 70/4 67/5 23/3 0.010
Ever use of biologic DMARDs (n)
  > 12 months 28 0 4 18 4 2 <0.001 0 5 15 6 2 <0.001
  ≤ 12 months 42 1 3 21 15 2 1 3 24 12 2
  ≤ 6 months 59 2 1 16 30 10 2 0 18 32 7
 Never 57 1 0 18 23 15 1 2 17 22 15
Serum uric acid (μmol/L) 362.7 ± 107.9 284.0 ± 95.3 345.1 ± 77.0 361.9 ± 105.5 366.0 ± 117.7 372.2 ± 97.8 0.593 284.0 ± 95.3 325.6 ± 103.5 362.3 ± 101.9 372.4 ± 118.8 363.3 ± 94.6 0.499
MSU crystallization (+/-) (n)
 Sacroiliac joint 111/261$ 0/4 0/8 14/59 29/43 14/15 <0.001 0/4 1/9 13/61 28/44 12/44 0.002
 Hip joint 75/111 1/3 4/4 33/40 28/44 9/20 0.632 1/3 6/4 32/42 29/43 7/19 0.369
 Pubic symphysis 63/123 0/4 3/5 25/48 28/44 7/22 0.244 0/4 4/6 25/49 29/43 5/21 0.112
Volume of MSU crystallization (cm3)
 Sacroiliac joint 0.29 ± 0.99$ NA NA 0.10 ± 0.30 0.31 ± 0.69 0.75 ± 1.72 0.001 NA 0.01 ± 0.01 0.10 ± 0.32 0.41 ± 1.19 0.83 ± 2.11 0.005
 Total volume at pelvis 4.37 ± 8.46 0.02 ± 0.03 0.63 ± 0.99 4.36 ± 8.01 4.92 ± 10.03 4.62 ± 6.72 0.077 0.02 ± 0.03 2.15 ± 4.16 4.00 ± 7.73 5.51 ± 10.37 3.78 ± 5.91 0.118
  1. Values are given as the numbers or the mean ± standard deviation (Mean±SD);
  2. AxSpA axial spondyloarthritis, n numbers, +/- positive/negative, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PGA patient’s global assessment, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath Ankylosing Spondylitis Functional Index, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease-modifying anti-rheumatic drugs, MSU monosodium urate, NA not available
  3. #All assessed on a visual analogue scale (0–10 cm)
  4. $The sum of the data from the left and right sacroiliac joint